Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Market Perform to Outperform. Analyst Price Forecast Suggests 42.56% ...

Lena Zewdu Feleke is a senior at Martin Luther King Jr. Magnet High School and a student from the School for Science and Math ...

It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...

The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million.

The Conference Forum today announced the launch of the 9th annual Patients as Partners® Europe event, taking place on May 20-21, 2025 at Royal National Hotel in London, UK. The meeting offers an ...

Federal agencies have removed web pages dedicated to DEI programs related to cancer research and other clinical research.

A recent executive order from President Donald J. Trump pausing trillions of dollars in federal grant and loan funding has ...